CA3180556A1 - Neutralizing antibodies against sars-related coronavirus - Google Patents

Neutralizing antibodies against sars-related coronavirus Download PDF

Info

Publication number
CA3180556A1
CA3180556A1 CA3180556A CA3180556A CA3180556A1 CA 3180556 A1 CA3180556 A1 CA 3180556A1 CA 3180556 A CA3180556 A CA 3180556A CA 3180556 A CA3180556 A CA 3180556A CA 3180556 A1 CA3180556 A1 CA 3180556A1
Authority
CA
Canada
Prior art keywords
seq
amino acid
variable region
acid sequence
chain amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3180556A
Other languages
English (en)
French (fr)
Inventor
Stephan Becker
Henning Grull
Florian Klein
Christoph KREER
Matthias ZEHNER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universitaet zu Koeln
Philipps Universitaet Marburg
Original Assignee
Universitaet zu Koeln
Philipps Universitaet Marburg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universitaet zu Koeln, Philipps Universitaet Marburg filed Critical Universitaet zu Koeln
Publication of CA3180556A1 publication Critical patent/CA3180556A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/102—Coronaviridae (F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/102—Coronaviridae (F)
    • C07K16/104—Severe acute respiratory syndrome coronavirus 2 [SARS‐CoV‐2]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CA3180556A 2020-05-29 2021-05-28 Neutralizing antibodies against sars-related coronavirus Pending CA3180556A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
EP20177354 2020-05-29
EP20177354.6 2020-05-29
EP20182325.9 2020-06-25
EP20182325 2020-06-25
EP20213562 2020-12-11
EP20213562.0 2020-12-11
PCT/EP2021/064326 WO2021239935A1 (en) 2020-05-29 2021-05-28 Neutralizing antibodies against sars-related coronavirus

Publications (1)

Publication Number Publication Date
CA3180556A1 true CA3180556A1 (en) 2021-12-02

Family

ID=76250344

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3180556A Pending CA3180556A1 (en) 2020-05-29 2021-05-28 Neutralizing antibodies against sars-related coronavirus

Country Status (6)

Country Link
US (1) US20210371503A1 (enExample)
EP (1) EP4157455A1 (enExample)
JP (1) JP2023528826A (enExample)
CA (1) CA3180556A1 (enExample)
TW (1) TW202210504A (enExample)
WO (1) WO2021239935A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118388640A (zh) * 2022-09-30 2024-07-26 郴州市第一人民医院 一种全人源抗新型冠状病毒SARS-CoV-2的广谱抗体及其应用

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20250107297A (ko) 2020-04-02 2025-07-11 리제너론 파아마슈티컬스, 인크. 항-sars-cov-2 스파이크 당단백질 항체 및 항원-결합 단편
BR112022024662A2 (pt) 2020-06-03 2023-04-04 Regeneron Pharma Métodos para tratamento ou prevenção de infecções por sars-cov-2 e covid-19 com anticorpos de glicoproteína spike anti-sars-cov-2
US20240383968A1 (en) * 2020-12-11 2024-11-21 Boehringer Ingelheim International Gmbh Formulation for multi-purpose application
AU2022221297A1 (en) * 2021-02-09 2023-08-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Antibodies targeting the spike protein of coronaviruses
WO2022263638A1 (en) * 2021-06-17 2022-12-22 Centre Hospitalier Universitaire Vaudois (C.H.U.V.) Anti-sars-cov-2 antibodies and use thereof in the treatment of sars-cov-2 infection
US12496470B2 (en) * 2021-07-14 2025-12-16 Regeneron Pharmaceuticals, Inc. Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments
WO2023150307A2 (en) * 2022-02-03 2023-08-10 Abpro Corporation Compositions and methods against a virus
WO2025194069A1 (en) * 2024-03-15 2025-09-18 Atreca, Inc. Anti-csp antibody variants

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4880078A (en) 1987-06-29 1989-11-14 Honda Giken Kogyo Kabushiki Kaisha Exhaust muffler
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
CA2109528A1 (en) 1991-05-01 1992-11-02 Gregory A. Prince A method for treating infectious respiratory diseases
US5934272A (en) 1993-01-29 1999-08-10 Aradigm Corporation Device and method of creating aerosolized mist of respiratory drug
US6019968A (en) 1995-04-14 2000-02-01 Inhale Therapeutic Systems, Inc. Dispersible antibody compositions and methods for their preparation and use
ATE508733T1 (de) 1996-03-04 2011-05-15 Penn State Res Found Materialien und verfahren zur steigerung der zellulären internalisierung
US5985309A (en) 1996-05-24 1999-11-16 Massachusetts Institute Of Technology Preparation of particles for inhalation
US5874064A (en) 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
US5855913A (en) 1997-01-16 1999-01-05 Massachusetts Instite Of Technology Particles incorporating surfactants for pulmonary drug delivery
CA2277801C (en) 1997-01-16 2002-10-15 Massachusetts Institute Of Technology Preparation of particles for inhalation
EP0979102A4 (en) 1997-04-30 2005-11-23 Enzon Inc DETAILED POLYPEPTIDE MODIFIED BY POLYALKYLENE OXIDE
WO1999066903A2 (en) 1998-06-24 1999-12-29 Advanced Inhalation Research, Inc. Large porous particles emitted from an inhaler
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
WO2005040219A1 (en) 2003-10-28 2005-05-06 Novo Nordisk A/S Laminin-5 gamma2-binding peptides, related compositions, and use thereof
AU2016356780A1 (en) 2015-11-19 2018-06-28 Bristol-Myers Squibb Company Antibodies against glucocorticoid-induced tumor necrosis factor receptor (GITR) and uses thereof

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118388640A (zh) * 2022-09-30 2024-07-26 郴州市第一人民医院 一种全人源抗新型冠状病毒SARS-CoV-2的广谱抗体及其应用

Also Published As

Publication number Publication date
WO2021239935A9 (en) 2023-07-13
US20210371503A1 (en) 2021-12-02
TW202210504A (zh) 2022-03-16
EP4157455A1 (en) 2023-04-05
WO2021239935A1 (en) 2021-12-02
JP2023528826A (ja) 2023-07-06

Similar Documents

Publication Publication Date Title
US20210371503A1 (en) Neutralizing antibodies against sars-related coronavirus
TWI859420B (zh) 抗sars-cov-2抗體及使用其之方法
US20230058162A1 (en) Multimeric coronavirus binding molecules and uses thereof
EP2744822B1 (en) Modified proteins and peptides
CN110016079B (zh) 抗呼吸道合胞病毒的中和抗体及其应用
JP6412107B2 (ja) Ｒｓｖｇタンパク質に結合するヒト抗体
JP2023523549A (ja) ＳＡＲＳ－ＣｏＶ－２に対する抗体およびそれを使用する方法
US20230242624A1 (en) HUMAN ANTIBODIES AGAINST SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS-2 (SARS-CoV-2)
US20240336672A1 (en) Human neutralizing monoclonal antibodies against sars-cov-2 and uses thereof
US12331104B2 (en) Hepatitis B antibodies
JP2024507948A (ja) 呼吸器ウイルス感染症に対する防御抗体
WO2021237516A1 (zh) Sars-cov-2抗体及其应用
WO2024175802A2 (en) SARS-CoV-2 NEUTRALIZING ANTIBODIES
CN116096402A (zh) 与抗人冠状病毒的中和抗体相关的方法和组合物
US20250154230A1 (en) Neutralizing antibodies against sars-related coronavirus
JP2012510802A (ja) 完全ヒトインフルエンザｍ２特異的抗体
EP4190810A1 (en) Neutralizing antibodies against sars-related coronavirus
CN116724049A (zh) 针对sars相关冠状病毒的中和抗体
CN114761428A (zh) 抗血凝素抗体及其使用方法
TW202204395A (zh) 抗sars-cov-2之抗體及使用其之方法
TWI868567B (zh) 冠狀病毒之特異性抗體及其用途
CN118660905A (zh) 针对sars相关冠状病毒的中和抗体
WO2023288078A1 (en) Coronavirus antibodies and uses thereof
KR20260048372A (ko) 녹농균에 대한 중화 인간 단클론 항체

Legal Events

Date Code Title Description
D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED

Effective date: 20250310

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250310

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250324

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT

Effective date: 20250507

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250512

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - SMALL

Year of fee payment: 4

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250519

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250519

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D120 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: VOLUNTARY SUBMISSION OF PRIOR ART RECEIVED

Effective date: 20250523

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D123 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIOR ART DISCLOSURE DETERMINED COMPLIANT

Effective date: 20250523

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250523

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250523

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D120 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: VOLUNTARY SUBMISSION OF PRIOR ART RECEIVED

Effective date: 20250822

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250911

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D120 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: VOLUNTARY SUBMISSION OF PRIOR ART RECEIVED

Effective date: 20250918

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D123 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIOR ART DISCLOSURE DETERMINED COMPLIANT

Effective date: 20251203

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251203

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260216

P22 Classification modified

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P22-P110 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CLASSIFICATION MODIFIED

Effective date: 20260220

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D123 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIOR ART DISCLOSURE DETERMINED COMPLIANT

Effective date: 20260226

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260226